ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Regorafenib modulates glucose metabolism, insulin/GLP-1 signaling, and tau pathology in an STZ-induced model of Alzheimer's disease.

Sadegh Salarinasab et al.PubMed ↗Publisher ↗

No numbers read from the abstract.